Evidence map›Paper›PMID 41891727›Full record

ReviewmBio2026

A brief historical perspective of antimicrobial resistance in India.

Maneesh Paul Satyaseela

Abstract readHistorical ArticleReview
In one paragraph

Review in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Maneesh Paul SatyaseelaMicrovioma Private Limited, Bengaluru, Karnataka, India.ORCID 0000-0002-6702-4942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is the ability of microbes to survive exposure to antimicrobials that were once effective against them. This is a major global crisis and public health challenge of the 21st century that is declared as a silent pandemic, with India among other countries considered one of the hotspots [R. Laxminarayan, A. Duse, C. Wattal, A. K. M. Zaidi, et al., Lancet Infect Dis 13:1057-1098, 2013, https://doi.org/10.1016/S1473-3099(13)70318-9]. The evolution of AMR in modern India's context is embedded in a complex interplay of the timing of antibiotic introduction, a growing dense population, cultural inheritances, infectious disease burden, developing health systems, evolving drug market regulations, environmental and animal sector drivers, socioeconomic factors, and policy/implementation gaps. Central to this discussion are the human patient, animal, and environmental aspects of antibiotic overuse from the historical aspects of AMR in India broadly tracing from early antibiotic use to the current "One Health" challenge. It highlights cultural factors, the evolution of surveillance systems, policy responses, India's efforts, and key lessons in antimicrobial stewardship.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsDrug Resistance, BacterialAnimalsHistory, 20th CenturyHistory, 21st CenturyHumansIndiaAnti-Bacterial AgentsAMRenmetazobactamIndiaNational Action Plan

Identifiers

PMID41891727
PMCPMC13170349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.